Drug-regulated CD33-targeted CAR T cells control AML using clinically optimized rapamycin dosing.
Appelbaum J, Price AE, Oda K, Zhang J, Leung WH, Tampella G, Xia D, So PP, Hilton SK, Evandy C, Sarkar S, Martin U, Krostag AR, Leonardi M, Zak DE, Logan R, Lewis P, Franke-Welch S, Ngwenyama N, Fitzgerald M, Tulberg N, Rawlings-Rhea S, Gardner RA, Jones K, Sanabria A, Crago W, Timmer J, Hollands A, Eckelman B, Bilic S, Woodworth J, Lamble A, Gregory PD, Jarjour J, Pogson M, Gustafson JA, Astrakhan A, Jensen MC.
Appelbaum J, et al. Among authors: timmer j.
J Clin Invest. 2024 Mar 19;134(9):e162593. doi: 10.1172/JCI162593.
J Clin Invest. 2024.
PMID: 38502193
Free PMC article.
Clinical Trial.